Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 8

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 8
---
million related to equipment. The impairment charge was triggered by a decision to discontinue an engineering project. During the three months ended March 31, 2024, the Company recorded impairment charges of $2.1 million related to computer equipment and software of which $0.3 million, $0.7 million and $1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the condensed consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project.

10

Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements

Compensation and Related BenefitsAccrued compensation and related benefits were comprised of the following (in thousands):March 31,2025December 31,2024Accrued payroll and related costs$6,303 $2,970 Accrued bonus7,648 21,859 Accrued commissions3,281 5,938 Other4,725 2,848 Accrued compensation and related benefits$21,957 $33,615 Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities were comprised of the following (in thousands):March 31,2025December 31,2024Legal and related costs$10,563 $6,100 Royalties for licensed technologies4,191 7,042 Professional services4,201 5,315 Product warranties9,453 8,615 Taxes payable4,775 4,936 Other12,300 9,157 Accrued expenses and other current liabilities$45,483 $41,165 Product WarrantiesChanges in the reserve for product warranties were as follows (in thousands):Three Months EndedMarch 31,20252024Beginning of period$8,615 $8,116 Amounts charged to cost of revenue3,965 2,355 Repairs and replacements(3,127)(764)End of period$9,453 $9,707 Revenue and Deferred RevenueAs of March 31, 2025, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements or allocated amounts for extended warranty service agreements bundled with sales of instruments was $33.5 million, of which approximately $20.9 million is expected to be recognized to